AZN vs MRK
AstraZeneca PLC and Merck & Co. Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AZN | MRK |
|---|---|---|
| Revenue | $58.7B | $65.0B |
| Net income | $10.2B | $18.3B |
| Gross margin | 81.9% | 74.8% |
| Net margin | 17.4% | 28.1% |
| Return on equity | 22.9% | 36.9% |
| Diluted EPS | $6.54 | $7.28 |
| Dividend / share | $3.13 | $3.28 |
| Payout ratio | 48.6% | 44.8% |
| Free cash flow | $11.8B | $12.4B |
| Equity | $48.7B | $52.6B |
| Net debt / equity | 0.49× | 0.66× |
| Current ratio | 0.94× | 1.54× |
| Revenue CAGR 5y | 17.2% | 9.4% |
| Profit CAGR 5y | 26.2% | 20.9% |
AZN and MRK book revenue within 15% of each other, and MRK keeps more of each dollar of revenue as profit (28.1% against 17.4%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AZN | MRK |
|---|---|---|
| FY2025 | $58.7B | $65.0B |
| FY2024 | $54.1B | $64.2B |
| FY2023 | $45.8B | $60.1B |
| FY2022 | $44.4B | $59.3B |
| FY2021 | $37.4B | $48.7B |
| FY2020 | $26.6B | $41.5B |
| FY2019 | $24.4B | $39.1B |
| FY2018 | $22.1B | $42.3B |
| FY2017 | $22.5B | $40.1B |
| FY2016 | $23.0B | $39.8B |
Bottom line
| Fiscal year | AZN | MRK |
|---|---|---|
| FY2025 | $10.2B | $18.3B |
| FY2024 | $7.0B | $17.1B |
| FY2023 | $6.0B | $365.0M |
| FY2022 | $3.3B | $14.5B |
| FY2021 | $112.0M | $13.0B |
| FY2020 | $3.2B | $7.1B |
| FY2019 | $1.3B | $9.8B |
| FY2018 | $2.2B | $6.2B |
| FY2017 | $3.0B | $2.4B |
| FY2016 | $3.5B | $3.9B |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$6,272,000,000 | MRK |
| FY2024 | −$10,095,000,000 | MRK |
| FY2023 | −$14,304,000,000 | MRK |
| FY2022 | −$14,932,000,000 | MRK |
| FY2021 | −$11,287,000,000 | MRK |
| FY2020 | −$14,901,000,000 | MRK |
| FY2019 | −$14,737,000,000 | MRK |
| FY2018 | −$20,204,000,000 | MRK |
| FY2017 | −$17,657,000,000 | MRK |
| FY2016 | −$16,805,000,000 | MRK |
| FY2015 | −$14,790,000,000 | MRK |
MRK has reported the higher revenue in every one of these 11 fiscal years. The gap has narrowed since the earliest year compared.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −10.7 pp | MRK |
| FY2024 | −13.7 pp | MRK |
| FY2023 | +12.4 pp | AZN |
| FY2022 | −17.1 pp | MRK |
| FY2021 | −26.5 pp | MRK |
| FY2020 | −5.2 pp | MRK |
| FY2019 | −20.0 pp | MRK |
| FY2018 | −5.4 pp | MRK |
| FY2017 | +6.7 pp | AZN |
| FY2016 | +4.9 pp | AZN |
| FY2015 | +0.1 pp | AZN |
The higher net margin has changed hands between AZN and MRK over this period.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRK's net margin has been more volatile than AZN's over the 11 comparable fiscal years — 9.1 percentage points of standard deviation against 4.6.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AZN and MRK over these 11 fiscal years — AZN led in 4 and MRK in 7.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRK's return on equity has been more volatile than AZN's over the 11 comparable fiscal years — 14.5 percentage points of standard deviation against 6.4.
11 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AZN and MRK over these 11 fiscal years — AZN led in 4 and MRK in 7.
11 of 18 comparable fiscal years — a year missing data on either side is not counted.